This improvement was accompanied by decreased KLF10 and TGFβ as well as recovered ChREBP expression in the liver, suggesting that enhanced KLF10 transcription might be related with NASH progression although the precise cause-and-effect mechanism should be delineated by another interventional study. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatohepatitis.